Metraipolis › archive › dc_2dd107fca411
Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system — Europe PMC PMID:41560737
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41560737
- DOI
- 10.3389/fphar.2025.1712361
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T01:38:57.137Z
- SHA-256 of the archived text
c0cd6aa3883a8ace88d19a3ae6860b227cba6e8e490ce482f5403e85472a90af- Stable URL of this page
https://metraipolis.com/documento/dc_2dd107fca411
How to cite
Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system — Europe PMC PMID:41560737 — Europe PMC (en), https://europepmc.org/article/MED/41560737 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2dd107fca411 (Metraipolis archive dc_2dd107fca411, sha256 c0cd6aa3883a8ace88d19a3ae6860b227cba6e8e490ce482f5403e85472a90af)
BibTeX
@misc{dc2dd107fca411,
title = {Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system — Europe PMC PMID:41560737},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41560737},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2dd107fca411; sha256 c0cd6aa3883a8ace88d19a3ae6860b227cba6e8e490ce482f5403e85472a90af},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41560737. Agents can read the archived copy with the MCP tool read_document.